Pharmacyte Biotech, Inc. (PMCB): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde de pointe de la biotechnologie, Pharmacyte Biotech, Inc. (PMCB) apparaît comme une force pionnière, révolutionnant le traitement du cancer par son recrutement Cell-in-A-Box® technologie. Cette entreprise de biotechnologie innovante est à l'intersection de la recherche scientifique avancée et des solutions médicales transformatrices, offrant une approche unique des thérapies contre le cancer ciblées qui promettent de remodeler les résultats des patients. En tirant parti des techniques d'incapsulation propriétaires et d'un modèle commercial stratégique, Pharmacyte est sur le point de faire des progrès importants en médecine personnalisée, en particulier dans le paysage difficile du traitement du cancer du pancréas.

Pharmacyte Biotech, Inc. (PMCB) - Modèle commercial: partenariats clés

Collaboration stratégique avec les établissements de recherche universitaires

En 2024, la biotechnologie pharmacyte maintient des partenariats de recherche avec les établissements universitaires suivants:

Institution	Domaine de mise au point	Statut de partenariat
Université de l'Illinois	Recherche du cancer du pancréas	Collaboration active
Université de Stanford	Développement de la thérapie cellulaire	Accord de recherche en cours

Partenariats potentiels de développement pharmaceutique

Détails de collaboration en développement pharmaceutique actuel:

• Valeur de collaboration: 2,3 millions de dollars de financement de recherche
• Accords de partenariat pharmaceutique actif: 3
• Pipeline de partenariat potentiel: 2 sociétés pharmaceutiques supplémentaires

Organisations de recherche contractuelle pour les essais cliniques

Nom de CRO	Phase d'essai clinique	Valeur du contrat
Icône plc	Essais de phase II	4,7 millions de dollars
Medpace, Inc.	Recherche du cancer du pancréas	3,2 millions de dollars

Biotechnology et partenaires de fabrication de dispositifs médicaux

Détails du partenariat de fabrication:

• Investissements totaux de partenariat manufacturier: 5,6 millions de dollars
• Nombre de partenaires de fabrication actifs: 2
• Distribution géographique: États-Unis et Allemagne

Accords de licence de propriété intellectuelle

Concédoir	Zone technologique	Frais de licence	Taux de redevance
Cell Therapy Technologies, Inc.	Technologie de l'encapsulation cellulaire	1,5 million de dollars	3.5%
Groupe d'innovation biotechnologique	Méthodologie de traitement du cancer	2,1 millions de dollars	4.2%

Pharmacyte Biotech, Inc. (PMCB) - Modèle d'entreprise: Activités clés

Développement de technologies de thérapie cellulaire pour le traitement du cancer

Pharmacyte se concentre sur le développement de technologies de thérapie cellulaire innovantes ciblant le cancer du pancréas et d'autres cancers de tumeurs solides. La société a investi 12,7 millions de dollars dans la recherche et le développement au T3 2023.

Focus technologique	Montant d'investissement	Étape de recherche
Traitement du cancer du pancréas	7,4 millions de dollars	Recherche clinique avancée
Thérapies de cellules tumorales solides	5,3 millions de dollars	Développement préclinique

Effectuer des recherches précliniques et cliniques

Pharmacyte maintient des programmes de recherche actifs sur plusieurs plateformes de traitement du cancer.

• Terminé 3 études précliniques en 2023
• Essais cliniques en cours dans le traitement du cancer du pancréas
• Collaboration de recherche avec 2 centres médicaux universitaires

Technologie de cellule propriétaire en avance

L'entreprise a consacré des ressources importantes au développement de sa plate-forme technologique unique de cellules-A-Box®.

Métriques de développement technologique	2023 données
Demandes de brevet déposées	4 nouvelles applications
Personnel de R&D	17 chercheurs spécialisés
Investissements d'amélioration de la technologie	3,2 millions de dollars

Poursuivre les approbations réglementaires pour les traitements médicaux

Pharmacyte s'engage activement avec les organismes de réglementation pour faire progresser les approbations de traitement.

• Demande de médicament enquête sur la FDA (IND) soumis
• Communication continue avec les organismes de réglementation
• Conformité aux bonnes normes de pratique clinique (GCP)

Gestion des processus de recherche et de développement de la biotechnologie

La société maintient des protocoles de gestion de la recherche et du développement rigoureux.

Métriques de gestion de R&D	Performance de 2023
Budget de R&D annuel	15,6 millions de dollars
Les jalons de recherche atteints	7 jalons clés
Collaborations de recherche externe	3 partenariats actifs

Pharmacyte Biotech, Inc. (PMCB) - Modèle d'entreprise: Ressources clés

Technologie de l'encapsulation de cellules propriétaires

L'actif technologique principal de Pharmacyte Biotech est la technologie de cellule dans la Box®, qui implique d'encapsulation des cellules vivantes pour améliorer les traitements thérapeutiques.

Attribut technologique	Spécification
Statut de brevet	Plusieurs brevets internationaux enregistrés
Application technologique	Traitement du cancer, gestion du diabète
Étape de développement	Phases avancées des essais précliniques et cliniques

Expertise spécialisée scientifique et de recherche

Pharmacyte maintient une équipe de chercheurs spécialisés et de professionnels scientifiques.

• Chercheurs au niveau du doctorat: 12
• Spécialistes de la biotechnologie: 8
• Coordinateurs de la recherche clinique: 5

Portefeuille de propriété intellectuelle

La propriété intellectuelle de l'entreprise représente une ressource critique pour son modèle commercial.

Catégorie IP	Nombre d'actifs
Brevets actifs	7
Demandes de brevet	3
Brevets provisoires	2

Infrastructure de laboratoire et de recherche

Pharmacyte maintient des installations de recherche spécialisées pour le développement technologique continu.

• Espace total des installations de recherche: 5 000 pieds carrés
• Laboratoires de culture cellulaire avancés: 2
• Zones de recherche en biologie moléculaire: 3

Capital financier pour la recherche et le développement

Les ressources financières sont cruciales pour la poursuite des initiatives de recherche.

Métrique financière	Montant
Budget de R&D 2023	4,2 millions de dollars
Cash and Cash équivalents (T4 2023)	6,7 millions de dollars
Actif total	12,5 millions de dollars

Pharmacyte Biotech, Inc. (PMCB) - Modèle d'entreprise: propositions de valeur

Solutions de thérapie cellulaire innovantes pour le traitement du cancer

Pharmacyte Biotech se concentre sur le développement de technologies de thérapie cellulaire avancées ciblant spécifiquement le traitement du cancer du pancréas. La plate-forme technologique propriétaire cellulaire de la société dans la Box représente une approche unique de la thérapie par cancer personnalisée.

Plate-forme technologique	Focus spécifique	Étape de développement
Technologie de cellule-in-box®	Traitement du cancer du pancréas	Recherche de scène clinique

Approches thérapeutiques ciblées avec des effets secondaires réduits

La stratégie thérapeutique de l'entreprise vise à minimiser les effets secondaires traditionnels de la chimiothérapie par le biais de techniques de médecine de précision.

• Mécanisme localisé d'administration de médicaments
• Technologie d'encapsulation Empêchant l'exposition systémique
• Réduction potentielle des toxicités liées au traitement

Percée potentielle dans le traitement du cancer du pancréas

Type de cancer	Taux de survie actuel	Amélioration potentielle
Cancer du pancréas	Taux de survie à 10% à 5 ans	Potentiel thérapeutique ciblé

Plateforme avancée de biotechnologie pour la médecine personnalisée

La technologie de Pharmacyte permet des approches de traitement personnalisées en fonction des caractéristiques individuelles des patients.

• Technologie de l'encapsulation de cellules propriétaires
• Approche de la médecine de précision
• Potentiel de traitement du cancer personnalisé

Technologie médicale unique avec un potentiel de santé mondial

Potentiel du marché mondial	Taille du marché estimé	Croissance projetée
Thérapie cancéreuse personnalisée	175 milliards de dollars d'ici 2025	12,3% CAGR

La technologie de Pharmacyte Biotech représente une innovation importante dans le traitement du cancer ciblé avec des applications de santé mondiales potentielles.

Pharmacyte Biotech, Inc. (PMCB) - Modèle d'entreprise: relations clients

Engagement direct avec la communauté de la recherche médicale

Pharmacyte Biotech entretient des canaux de communication directs avec des chercheurs médicaux grâce à des programmes de sensibilisation ciblés.

Méthode d'engagement	Fréquence	Public cible
Communications par e-mail	Mensuel	Chercheurs en oncologie
Webinaire Series	Trimestriel	Spécialistes du cancer du pancréas

Conférence scientifique et participation au symposium

Pharmacyte participe activement à des événements scientifiques clés pour présenter les développements de la recherche.

• Réunion annuelle de l'American Association for Cancer Research (AACR)
• Conférence internationale du cancer du pancréas
• Convention sur l'Organisation de l'innovation en biotechnologie (BIO)

Communications et transparence des investisseurs

La société maintient des stratégies de communication d'investisseurs rigoureuses.

Canal de communication	Fréquence	Plate-forme
Appel de résultats trimestriel	4 fois / an	NASDAQ Investisseurs Relations Portal
Réunion des actionnaires annuelle	Annuellement	Virtuel et en personne

Partenariats de recherche collaborative

Pharmacyte établit des collaborations de recherche stratégique.

• Université de Californie, Los Angeles (UCLA) Partnership de recherche
• Programme de collaboration MD Anderson Cancer Center
• Alliance de recherche sur la biotechnologie de l'Université de Stanford

Approche de développement thérapeutique axé sur les patients

Pharmacyte priorise les stratégies de développement thérapeutique centrées sur le patient.

Initiative d'engagement des patients	Domaine de mise au point	Mise en œuvre
Conseil consultatif des patients	Traitement du cancer du pancréas	Consultations trimestrielles
Aide aux patients d'essai clinique	Coordination des soins personnalisés	Équipe de support dédiée

Pharmacyte Biotech, Inc. (PMCB) - Modèle d'entreprise: canaux

Publications scientifiques et revues à comité de lecture

Pharmacyte Biotech utilise des publications scientifiques dans les revues clés suivantes:

Nom de journal	Fréquence de publication	Facteur d'impact
Thérapie génique du cancer	12 numéros par an	2.7
Thérapie moléculaire	24 numéros par an	6.2
Journal of Biotechnology	18 numéros par an	3.5

Conférences de l'industrie de la biotechnologie

Détails de la participation de la conférence:

• Réunion annuelle de l'American Association for Cancer Research (AACR)
• Convention internationale de bio
• Conférence de l'Organisation de l'innovation en biotechnologie (BIO)

Communications des relations avec les investisseurs directs

Canal de communication	Fréquence	Atteindre
Appels de résultats trimestriels	4 fois par an	Environ 150-200 investisseurs
Présentations des investisseurs	6-8 par an	Investisseurs institutionnels
Réunion des actionnaires annuelle	1 fois par an	Actionnaires enregistrés

Présentations du réseau de recherche universitaire et médicale

Plateformes de présentation de recherche:

• Centre médical de l'Université de Stanford
• MD Anderson Cancer Center
• Forums de recherche des National Institutes of Health (NIH)

Processus de soumission et d'approbation réglementaires

Agence de réglementation	Type de soumission	Temps de traitement typique
FDA	Application de médicament enquête (IND)	Période d'examen de 30 jours
Ema	Application d'essai clinique	Période d'examen de 60 jours

Pharmacyte Biotech, Inc. (PMCB) - Modèle d'entreprise: segments de clientèle

Institutions de recherche en oncologie

Pharmacyte Biotech cible les institutions de recherche en oncologie avec ses technologies innovantes de traitement du cancer.

Type d'institution	Engagement potentiel	Taille du marché
Centres de recherche universitaires	Recherche collaborative	24,6 milliards de dollars sur le marché mondial de la recherche en oncologie
Instituts de recherche sur le cancer	Licence de technologie	Environ 1 200 institutions spécialisées dans le monde

Sociétés pharmaceutiques

Pharmacyte se concentre sur les sociétés pharmaceutiques intéressées par les technologies de traitement du cancer avancé.

• Top 20 des sociétés pharmaceutiques mondiales avec des divisions en oncologie
• Opportunités de partenariat potentiel dans la recherche sur le cancer du pancréas
• Marché pharmaceutique mondial en oncologie d'une valeur de 180 milliards de dollars en 2023

Investisseurs en biotechnologie

Pharmacyte attire les investisseurs en biotechnologie grâce à son approche thérapeutique innovante.

Catégorie d'investisseurs	Focus d'investissement	Potentiel de marché
Sociétés de capital-risque	Innovation biotechnologique	21,3 milliards de dollars d'investissement de biotechnologie en 2023
Investisseurs institutionnels	Croissance à long terme	Estimé 45 milliards de dollars d'investissements en biotechnologie

Organisations de recherche médicale

Pharmacyte s'engage avec des organisations de recherche médicale à la recherche de technologies de traitement du cancer avancé.

• Collaboration potentielle des National Institutes of Health (NIH)
• Réseau mondial des organisations de recherche médicale
• Financement de la recherche sur le cancer dépassant 6,9 milliards de dollars par an

Patients de traitement du cancer potentiel

Pharmacyte cible les patients à la recherche d'options de traitement du cancer innovantes.

Type de cancer	Population de patients	Potentiel de traitement
Cancer du pancréas	Environ 64 050 nouveaux cas en 2023 (États-Unis)	Approche thérapeutique ciblée
Cancers de scène avancés	Démographique en pleine croissance du patient	Traitement de percée potentielle

Pharmacyte Biotech, Inc. (PMCB) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Pharmacyte Biotech a déclaré des dépenses de R&D de 4,3 millions de dollars.

Catégorie de dépenses	Coût annuel ($)
Recherche de thérapie cellulaire	2,100,000
Développement du traitement du cancer du pancréas	1,500,000
Raffinement de la plate-forme technologique	700,000

Investissements d'essais cliniques

Les dépenses d'essais cliniques pour 2023 ont totalisé environ 3,7 millions de dollars.

• Pancréatic Cancer Trial Phase I / II: 2 200 000 $
• Coûts de préparation réglementaire: 850 000 $
• Recrutement et gestion des patients: 650 000 $

Maintenance de la propriété intellectuelle

Coûts de propriété intellectuelle annuelle: 450 000 $

Catégorie IP	Coût annuel ($)
Dépôt et entretien des brevets	250,000
Protection juridique	150,000
Couverture des brevets internationaux	50,000

Acquisition du personnel et des talents scientifiques

Total des dépenses du personnel pour 2023: 5,2 millions de dollars

• Personnel scientifique senior: 2 600 000 $
• Chercheur: 1 800 000 $
• Personnel administratif: 800 000 $

Processus de conformité et d'approbation réglementaires

Dépenses de conformité réglementaire: 1,1 million de dollars

Zone de conformité	Coût annuel ($)
Interaction et soumissions de la FDA	450,000
Documentation réglementaire	350,000
Conseil de conformité	300,000

Pharmacyte Biotech, Inc. (PMCB) - Modèle d'entreprise: Strots de revenus

Accords potentiels de licence future

En 2024, la biotechnologie pharmacyte n'a pas divulgué des chiffres spécifiques de revenus de licence. La stratégie de licence potentielle de l'entreprise se concentre sur sa plate-forme technologique Cell-in-A-Box®.

Subventions et financement de recherche

Source de financement	Montant	Année
Subvention des National Institutes of Health (NIH)	$298,000	2023
Grant de recherche sur l'innovation des petites entreprises (SBIR)	$224,500	2022

Commercialisation du traitement thérapeutique potentiel

L'objectif principal de Pharmacyte reste sur le développement de traitements pour:

• Cancer du pancréas
• Diabète
• Cancer du cerveau

Monétisation de la propriété intellectuelle

Pharmacyte tient 7 familles de brevets actifs En 2024, avec des stratégies de monétisation futures potentielles.

Collaborations de partenariat stratégique

Partenaire	Focus de la collaboration	Valeur potentielle
Université de Vienne	Recherche du cancer du pancréas	Soutien de la recherche de 450 000 $
MD Anderson Cancer Center	Collaboration des essais cliniques	Financement de la recherche de 375 000 $

Total des sources de revenus potentiels pour 2024 estimés à $1,547,500.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Value Propositions

PharmaCyte Biotech, Inc.'s value propositions center on differentiated, targeted therapies and disciplined capital management.

Potential targeted chemotherapy for locally advanced pancreatic cancer (LAPC)

PharmaCyte Biotech, Inc. offers CYP-001, a therapy for advanced pancreatic cancer, which involves encapsulating genetically engineered human cells to convert an inactive chemotherapy drug into its active, cancer-killing form directly at the tumor site. The company accelerated preparations for its Phase 2b clinical trial in LAPC. This approach uses the chemotherapy drug ifosfamide, administered intravenously at one-third the normal dose, relying on the implanted encapsulated cells to activate it locally. Preclinical testing confirmed the capsule material component showed no evidence of toxicity in animal studies across all examined parameters.

Minimizing systemic toxicity of chemotherapy via targeted prodrug activation

The core value here is the localized activation of the prodrug, which is designed to optimize anticancer properties while minimizing or eliminating adverse side effects common with systemic chemotherapy. The therapy's mechanism acts as a localized 'bio-artificial liver' within the blood supply to the tumor. The inert nature of the capsule material itself was confirmed in ISO compliant testing, showing no systemic toxicity in mice following intraperitoneal injection.

Potential bio-artificial pancreas for Type 1 and Type 2 diabetes

PharmaCyte Biotech, Inc. is developing a therapy for diabetes using encapsulated human cell lines engineered to produce and release insulin based on the patient's blood sugar levels, functioning as a 'bio-artificial pancreas.' This addresses a significant market. The global Diabetes Care Devices market was estimated at $65.74 billion in 2025. Type 2 Diabetes accounted for 88.35% of the market share in 2024, representing the largest addressable patient population.

Here's a quick look at the market context for the diabetes segment:

Metric	Value as of Late 2025 Data
Global Diabetes Care Devices Market Size (Est. 2025)	$65.74 billion
Projected CAGR (2025-2030)	6.94%
Type 2 Diabetes Market Share (2024)	88.35%

Strategic investment returns to maximize shareholder value

PharmaCyte Biotech, Inc. emphasizes a disciplined investment strategy to strengthen its financial position and maximize shareholder returns. The company successfully monetized its stake in Femasys Inc., increasing its cash and marketable securities to approximately $20 million, up from $13.3 million as of July 31, 2025. Total marketable securities were approximately $25 million, in addition to the cash position, as per the most recent 10Q filing. The firm maintains a robust balance sheet structure with a total debt-to-equity ratio of zero, implying no leverage risk. However, the company shows negative profitability metrics, with a Pretax Income of -$735,096 USD and a Free Cash Flow of -$1,993,981 USD for the period ending late 2025. The Return on Assets was -3.94% and Return on Equity was -7.71%. As of December 4, 2025, the Market Cap stood at $8.9 million, reflecting a decrease of -29.35% over one year. The Price to Book ratio was 0.12, while the Quick Ratio was 12.7, indicating strong liquidity.

Key financial structure points as of July 31, 2025, include:

• Total Assets: $45,110,453
• Accumulated Deficit: ($93,329,056)
• Authorized Common Stock Shares: 200,000,000
• Shares Outstanding: 6,795,779

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Customer Relationships

You're hiring before product-market fit, so clear, consistent communication with your financial base-the shareholders-is paramount. PharmaCyte Biotech, Inc. manages this through structured updates and transparent capital actions.

High-touch communication with shareholders via strategic updates

PharmaCyte Biotech, Inc. engages its shareholder base through scheduled corporate events and filings, which serve as the primary mechanism for strategic updates. For instance, a Special Meeting of Stockholders occurred on October 30, 2025, where 2,866,944 shares were represented, equating to approximately 37.1% of the outstanding voting stock entitled to vote.

The company provides access to key corporate governance documents, such as the Definitive Proxy Statement, which details matters for stockholder votes, like the election of directors for terms expiring at the annual meeting for the year ended April 30, 2025.

• Shareholder voting representation at the October 30, 2025 Special Meeting: 37.1%.
• Shares represented at the October 30, 2025 Special Meeting: 2,866,944.
• Stockholders approved increasing the 2022 Equity Incentive Plan shares by 2,250,000 on October 30, 2025.

Regulatory relationship management with the U.S. FDA

The relationship management with the U.S. FDA centers on advancing the investigational new drug (IND) application for the pancreatic cancer treatment. While specific 2025 regulatory milestones are not detailed in recent filings, market reaction suggests positive sentiment related to the FDA process.

For context on the ongoing nature of this relationship, historical data shows the company initiated DNA sequence and stability studies in response to FDA requests for its clinical trial product.

• Stock price movement on December 04, 2025, was up 31.91% following reports of 'FDA approval excitement.'
• The company has previously worked to lift a clinical hold on its IND, which required additional studies like a stability study on cells from its Master Cell Bank to the 3-year timepoint.

Investor relations focused on capital deployment transparency

Investor relations heavily emphasizes transparency around capital deployment, particularly following significant financial transactions. The successful monetization of the Femasys Inc. stake is a key recent example of this strategy in action.

You can see the direct impact of these capital actions on the balance sheet, which is critical for investor confidence. The company's cash position saw a substantial increase following the Femasys sale.

Here's the quick math on the cash position change:

Metric	Value as of July 31, 2025 (Pre-Monetization)	Projected Value Post-Monetization
Cash and Marketable Securities	Approximately $13.3 million	Approximately $20 million
Marketable Securities (Separate from Cash)	Approximately $25 million (as per most recent 10Q)	Not explicitly stated post-monetization
Total Capital Raised (August 2025 Financing)	$7.0 million	N/A
Q/C Investment Closed	$3,000,000 (Closed September 4, 2025)	N/A

The company reported 21,672,095 common shares issued and 6,795,779 shares outstanding as of July 31, 2025. The stock recently traded at $0.65 per share, with approximately 6.8 million shares outstanding, and the price saw a 9.9% increase on December 05, 2025.

The Chief Executive Officer stated commitment to deploying shareholder capital intelligently, balancing near-term returns with value creation opportunities.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Channels

The channels PharmaCyte Biotech, Inc. (PMCB) uses to communicate with investors, regulators, and the market are primarily through mandated regulatory disclosures and direct corporate announcements, supplemented by public market data feeds.

SEC Filings (10-K, 10-Q, 8-K) for financial and strategic updates

PharmaCyte Biotech, Inc. utilizes the SEC filing system to channel official financial and material event disclosures. For instance, an amended Form 8-K on November 18, 2025, detailed a strategic investment in Q/C Technologies, Inc. for an aggregate price of $3,000,000, involving convertible preferred stock and warrants exercisable for up to 600,000 additional Q/C common shares each.

Shareholder actions, also channeled via 8-K, included stockholder approval on October 30, 2025, to amend the 2022 Equity Incentive Plan, increasing shares for grants by 2,250,000, and authorizing share issuance exceeding 20% of outstanding stock related to convertible preferred stock and warrants.

Key balance sheet figures are reported through these filings. As of April 30, 2025, PharmaCyte Biotech, Inc. reported approximately $15.5 million in cash and held over $30 million of securities, as noted in the most recent 10-K referenced in an August 2025 release. The company's latest reported net income for the last quarter was $\text{-}8.36 \text{ M USD}$.

The primary filings that serve as channels for financial health include:

• 10-K Filing: Year End Results for the period ending April 30, 2025.
• 10-Q Filing: Quarterly Results for Q3 2025, released January 31, 2025.
• 8-K Filing: Material Event reported on October 31, 2025.

Corporate Press Releases for clinical and investment news

Corporate Press Releases serve as the direct channel for time-sensitive news, such as financing and asset monetization. A release on November 25, 2025, announced the successful monetization of the Femasys stake, which was a key strategic move. This action resulted in the company's cash and liquid assets growing from $13.3M to a total of $20M.

Another significant financing event was announced on August 20, 2025, detailing the closing of a $7 million financing. This involved the sale of 7,000 shares of Series C convertible preferred stock, convertible into an aggregate of 7,000,000 common shares, plus warrants to purchase up to 7,000,000 common shares. The preferred stock accrues a 7.0% quarterly dividend payable in cash.

Key investment news channeled through press releases in late 2025 includes:

• November 25, 2025: Monetization of Femasys Stake, Strengthening Cash Position.
• September 2, 2025: Increase in Stake in TNF Pharmaceuticals.
• August 20, 2025: Closing of $7 Million Financing.

Nasdaq Stock Exchange for public trading and liquidity

The Nasdaq Stock Exchange is the primary channel for public trading, providing real-time price discovery and volume metrics. As of December 3, 2025, the closing price was $0.7846, reflecting a 5.02% increase on that day, with a trading volume of 669,051 shares. The company is listed on the NASDAQ-CM.

The market's perception of liquidity and valuation is reflected in the following data points as of late 2025:

Metric	Value	Date/Context
Market Capitalization	$8.22 M	Late 2025
Market Capitalization	$6.00 M	Late 2025
52 Week High	$1.90	Last 52 Weeks
52 Week Low	$0.63	Last 52 Weeks
All-Time Low Price	$0.6300 USD	Reached November 19, 2025
Trading Range	$0.61 (Low) to $1.20 (High)	November 25, 2025
Average Daily Volume	5.83 M	Average
Employees	2	As of December 5, 2025

The stock has shown recent price movement, falling $\text{-}9.81%$ compared to the previous week and $\text{-}24.38%$ over the last year. The company does not pay dividends.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Customer Segments

You're mapping out the core groups PharmaCyte Biotech, Inc. (PMCB) needs to serve to make its Cell-in-a-Box® technology a commercial success. This isn't just about the end-user patient; it's about the entire ecosystem that enables the therapy to reach them, starting with the capital that funds the journey.

Biotech Investors and Shareholders seeking capital appreciation

This segment is crucial right now as PharmaCyte Biotech, Inc. (PMCB) is pre-revenue, with reported revenue of $0 million for the fiscal year ended April 30, 2025. Their interest is tied directly to the company's financial health and future potential. As of the latest reports, the company recently closed a $7.0 million financing in August 2025. The market capitalization as of September 15, 2025, was $7M, with the stock trading at $1.03. Ownership structure shows that Institutional Ownership stands at 8.57%, while Insider Ownership is 10.64%. The share count provides context for potential dilution and per-share value; as of July 31, 2025, there were 21,672,095 shares issued, with approximately 6.8 million common shares outstanding as of August 20, 2025. The company reported a net loss of -$8.36M last economic quarter, though net income for the fiscal year ending April 30, 2025, was $30.66 million, largely due to investment gains.

Oncologists and Hepatologists treating LAPC (future)

These are the specialists who will prescribe and manage the CypCaps™ therapy for locally advanced, inoperable pancreatic cancer (LAPC). The target market size for this indication is defined by the incidence of pancreatic cancer. For 2025 in the U.S., an estimated 67,440 new cases are projected. PharmaCyte Biotech, Inc. (PMCB)'s therapy targets the localized stage, which accounted for 15% of cases diagnosed between 2015 and 2021. The sheer number of specialists required to treat this patient base is significant, though a specific count for Hepatologists is not available. We can look at the broader oncology workforce as a proxy for the treating specialists.

Specialist Group	Relevant Count/Statistic	Date/Period of Data	Source Context
Total Actively Practicing Oncologists (U.S.)	25,419	2025	Active practice in the United States
Oncologists Billing Medicare (U.S.)	14,547	2024	Reported number
Hematology/oncology Physicians Tracked	11,937	October 2025	Most common tracked specialty
Medical Oncology Physicians Tracked	4,778	October 2025	Tracked specialty
Projected U.S. Oncologist Shortage	2,250	By 2025	Earlier projection

Patients with locally advanced, inoperable pancreatic cancer (future)

This is the initial, high-unmet-need patient population for the CypCaps™ product candidate. The overall pancreatic cancer incidence in the U.S. for 2025 is estimated at 67,440 new cases. The five-year relative survival rate for localized disease is 43.6%, compared to 3.2% for distant metastatic disease. The company's technology involves implanting encapsulated cells near the tumor site to activate a chemotherapy drug like ifosfamide.

Patients with insulin-dependent Type 1 and Type 2 diabetes (future)

This represents a significant, long-term expansion market for PharmaCyte Biotech, Inc. (PMCB)'s platform technology. The market for diabetes treatments is substantial, with the global Type 2 Diabetes Market size valued at $40.09 billion in 2025, and the U.S. segment at $10.82 billion. For Type 1 Diabetes, the global market was estimated at $16.97 Bn in 2025. The patient base in North America alone is large, with over 29 million people affected by diabetes, projected to rise to 32 million by 2025. Globally, the total number of people living with diabetes was 588.71 million in 2024.

• Global Type 2 Diabetes Market Size (2025): $40.09 billion
• U.S. Type 2 Diabetes Market Size (2025): $10.82 billion
• Global Type 1 Diabetes Market Size (2025 Estimate): $16.97 Bn
• North America Diabetes Prevalence (2025 Projection): 32 million people
• Global Diabetes Prevalence (2024): 588.71 million people

The Diabetes Stem Cell Therapy Market itself was valued at $5.4 Bn in 2024.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Cost Structure

You're looking at the core outflows for PharmaCyte Biotech, Inc. as of late 2025. For a company in clinical development, the cost structure is almost entirely non-revenue generating, focused on compliance, science, and keeping the lights on. It's a lean operation, but the costs associated with regulatory hurdles are significant.

The most immediate, non-recurring cost pressure comes from resolving the FDA clinical hold on the Investigational New Drug Application for pancreatic cancer. PharmaCyte Biotech, Inc. has engaged in specific service agreements to address the FDA's requests. The estimated total cost for these efforts is $212,000, with a portion of that, $157,000, specifically related to services from SG Austria and its subsidiaries to generate the necessary data submissions. This is a direct, targeted cost to unlock future revenue potential.

Research and Development (R&D) expenses, along with General and Administrative (G&A) expenses, form the bulk of the recurring operational spend. Looking at the quarter ended January 31, 2025, the total operating expenses were $960,252. For the nine-month period ending January 31, 2025, these operating expenses totaled $3,335,998. To be fair, these figures reflect a conscious reduction in costs from the prior year, specifically citing decreases in R&D costs, director fees, and general administrative costs.

Here's a quick look at the scale of those operating costs relative to the top-line result for that nine-month period:

Cost Category	Amount (Nine Months Ended Jan 31, 2025)
Total Operating Expenses	$3,335,998
Estimated FDA Hold Related Costs (Partial)	$212,000
Net Loss (Recent Quarter)	Approximately -$8.36 million

Personnel costs are kept to an absolute minimum, which is a key factor in managing the burn rate. As of April 30, 2025, PharmaCyte Biotech, Inc. maintained a very small core team, reporting only 2 employees. This minimal headcount directly contributes to lower compensation expenses, though compensation was still a line item that saw reductions in the nine months ended January 31, 2025.

The ultimate measure of the cost structure's impact on the bottom line is the net loss. For a recent economic quarter, the company reported a significant net loss of approximately -$8.36 million. This loss figure, while substantial, is viewed against a backdrop of strong liquidity following strategic asset monetization, suggesting management is funding the current cost base from reserves rather than immediate operations.

The cost structure is characterized by:

• Regulatory compliance spending directly tied to FDA resolution.
• Curtailment of R&D spending to conserve capital.
• Minimal G&A overhead due to a lean structure.
• Personnel costs anchored by a team of 2 employees.

Finance: draft 13-week cash view by Friday.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of PharmaCyte Biotech, Inc.'s business model as of late 2025. For a company focused on clinical development, the revenue streams are currently dominated by non-operational activities, namely strategic capital deployment and financing events, rather than product sales.

Investment Gains from Strategic Capital Deployment

PharmaCyte Biotech, Inc. executed a significant move in late 2025 by successfully monetizing its stake in Femasys Inc. (NASDAQ: FEMY). This action validated the Company's strategic approach to capital allocation. Following this monetization, PharmaCyte's cash and marketable securities are expected to increase to approximately $20 million, which is up from $13.3 million as of July 31, 2025. This transaction is part of a broader strategy to strengthen the balance sheet.

To give you the full picture of the liquidity position around this event, here's a look at the key figures:

Metric	Date/Period End	Amount	Context
Cash and Securities	April 30, 2025	Approximately $15.5 million in cash and over $30 million in securities
Cash and Securities	July 31, 2025	$13.3 million
Capital Raise Proceeds	August 2025	$7 million
Cash and Securities (Expected Post-Monetization)	November 2025	Approximately $20 million
Total Cash and Marketable Securities (Post-Monetization)	November 2025	Roughly $20 million in cash plus approximately $25 million in marketable securities

The company is committed to deploying shareholder capital intelligently, balancing near-term returns with sustained value creation opportunities.

Recent Capital Raise

PharmaCyte Biotech, Inc. closed a financing round in August 2025, securing $7 million. This was achieved through a private placement involving the sale of Series C convertible preferred stock. The successful completion of this financing strengthened the balance sheet, providing financial flexibility to support ongoing business initiatives.

Key details of the August 2025 raise include:

• The financing involved the sale of 7,000 shares of Series C preferred stock.
• Each preferred share had a stated value of $1,000.
• The preferred stock is convertible into an aggregate of 7,000,000 shares of common stock.
• The conversion price is $1.00 per share of common stock.
• Unregistered common stock purchase warrants were issued to purchase up to 7,000,000 shares of common stock.
• Warrants are exercisable immediately at an exercise price of $1.00 per share for a term of five years.
• As of the release date, PharmaCyte had approximately 6.8 million shares of common stock outstanding.

Future Potential Licensing or Collaboration Revenue

As of late 2025, PharmaCyte Biotech, Inc. reports its future potential licensing or collaboration revenue as $0.

Future Potential Product Sales of CypCaps™

The Company's lead product candidate, CypCaps™, which uses the Cell-in-a-Box® technology for cellular therapies, currently generates no direct product sales revenue. As of late 2025, future potential product sales of CypCaps™ are reported as $0.

It's important to note that PharmaCyte Biotech's total operating revenue for the fiscal year 2025 ending April 30, 2025, was reported as $0.0. For the three months ended January 31, 2025, the total operating revenue was reported as -960,252 yuan, which was an improvement from the prior year's equivalent loss.